United Therapeutics (UTHR) Interest Expenses (2009 - 2026)

United Therapeutics has disclosed Interest Expenses across 18 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Interest Expenses fell 60.27% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $12.0 million (down 61.78% YoY), while the FY2025 annual figure was $19.5 million, down 54.55% from the prior year.
• Interest Expenses came in at $2.9 million for Q2 2026 at United Therapeutics, down from $3.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $15.6 million in Q3 2023 to a low of $2.9 million in Q2 2026.
• Average Interest Expenses over 5 years is $8.9 million, with a median of $8.5 million recorded in 2022.
• Year-over-year, Interest Expenses surged 193.62% in 2023 and slumped 70.3% in 2025.
• Over 5 years, Interest Expenses stood at $12.3 million in 2022, then advanced by 22.76% to $15.1 million in 2023, then plunged by 47.68% to $7.9 million in 2024, then slumped by 60.76% to $3.1 million in 2025, then decreased by 6.45% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $2.9 million in Q2 2026, $3.0 million in Q1 2026, and $3.1 million in Q4 2025.